NORPROLAC DIN 02223767
Status: Cancelled Post Market
Holder: FERRING INC
Health Canada record
| Active ingredient(s) | QUINAGOLIDE (QUINAGOLIDE HYDROCHLORIDE) 0.075 MG |
|---|
| Dosage form | Tablet |
|---|
| Route | Oral |
|---|
| Schedule | PRESCRIPTION |
|---|
| Class | Human |
|---|
| ATC | G02CB04 QUINAGOLIDE |
|---|
| Original market date | 29-Dec-2004 |
|---|
| Current status date | 09-Dec-2020 |
|---|
| Source | Health Canada DPD |
|---|
Establishment licence of the holder
Ferring Inc. — licence 100274, currently licensed, last inspection rating C (2026-05-19).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing QUINAGOLIDE (QUINAGOLIDE HYDROCHLORIDE)
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02223740 | NORPROLAC | FERRING INC | Tablet | QUINAGOLIDE (QUINAGOLIDE HYDROCHLORIDE) 0.025 MG | Cancelled Post Market |
| 02223759 | NORPROLAC | FERRING INC | Tablet | QUINAGOLIDE (QUINAGOLIDE HYDROCHLORIDE) 0.05 MG | Cancelled Post Market |
| 02223775 | NORPROLAC | FERRING INC | Tablet | QUINAGOLIDE (QUINAGOLIDE HYDROCHLORIDE) 0.15 MG | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 153 | 2004-03-15 | New Drug Submission (NDS) | MANUFACTURER NAME CHANGE |
| 4606 | 1996-06-25 | New Drug Submission (NDS) | |
Request a quote for NORPROLAC
How to read a Canadian DIN record